ResMed vs Danaher: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

ResMed Inc (RMD)

Q3 20267 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

August 20267 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

Latest7 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

Danaher Corporation (DHR)

Q3 202624 Jun – 4 Aug 2026

▼3▲1

Danaher's Masimo Deal and Guidance Cut Pressure Shares

Masimo Acquisition Drag Danaher's $9.9 billion purchase of Masimo sent shares down 22% due to debt, integration challenges, and Apple patent disputes. This major deal overshadowed positive product news.
The acquisition is the biggest new event and main reason for the stock's decline.
Guidance Cut on Weak Respiratory Testing Danaher lowered its full-year core revenue growth forecast to 4% from 6%, blaming weaker respiratory testing and over $100 million in bioprocessing revenue shifting to 2027.
This guidance cut directly impacts investor expectations and the stock's valuation.
Biotech Consumables Shipment Timing Miss Biotech consumables missed expectations due to shipment timing, raising fears of broader weakness despite strong underlying demand. This added to concerns about the bioprocessing business.
The miss highlights execution risks and weighs on sentiment.
Strong Biotech Growth and Product Approvals Danaher posted 7% core biotech growth, strong bioprocessing orders, FDA clearance for Masimo's AI opioid-detection feature, and a CE Mark for Beckman Coulter's Alzheimer's blood test. Q2 EPS beat and guidance was raised.
These positives show underlying business strength and innovation, providing a counterweight to the negatives.

July 202624 Jun – 4 Aug 2026

▼3▲1

Danaher's Masimo Deal and Guidance Cut Pressure Shares

Masimo Acquisition Drag Danaher's $9.9 billion purchase of Masimo sent shares down 22% due to debt, integration challenges, and Apple patent disputes. This major deal overshadowed positive product news.
The acquisition is the biggest new event and main reason for the stock's decline.
Guidance Cut on Weak Respiratory Testing Danaher lowered its full-year core revenue growth forecast to 4% from 6%, blaming weaker respiratory testing and over $100 million in bioprocessing revenue shifting to 2027.
This guidance cut directly impacts investor expectations and the stock's valuation.
Biotech Consumables Shipment Timing Miss Biotech consumables missed expectations due to shipment timing, raising fears of broader weakness despite strong underlying demand. This added to concerns about the bioprocessing business.
The miss highlights execution risks and weighs on sentiment.
Strong Biotech Growth and Product Approvals Danaher posted 7% core biotech growth, strong bioprocessing orders, FDA clearance for Masimo's AI opioid-detection feature, and a CE Mark for Beckman Coulter's Alzheimer's blood test. Q2 EPS beat and guidance was raised.
These positives show underlying business strength and innovation, providing a counterweight to the negatives.

Latest25 Jul – 4 Aug 2026

▲3▼1

Danaher cuts growth outlook, but core biotech and diagnostics still support

Full-year core revenue growth outlook cut to 4% from 6% Danaher lowered the top end of its 2026 core revenue growth forecast to 4% from 6%, citing weaker respiratory testing and over $100 million in bioprocessing revenue shifting to next year. This signals slower demand ahead, pushing the stock down as investors worry about future growth.
This is the main new negative event that directly answers why DHR is moving right now.
Q2 earnings beat and raised EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45–$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.
This is a new positive counterweight that helps explain the mixed picture and potential support for the stock.
Biotech orders grow mid-teens, but revenue timing shifts Danaher's bioprocessing orders grew mid-teens, indicating strong underlying demand, but weaker-than-expected biotechnology revenue and a shift of over $100 million into next year weighed on results. This creates a mixed picture: strong future demand but near-term revenue miss.
This explains the nuance behind the revenue miss and why the stock reaction may be overdone.
Analysts see stock as undervalued after sell-off A Simply Wall St analysis suggests Danaher is 16% undervalued based on earnings and 2026 revenue guidance, with a fair value estimate of $228.61. BofA maintained a Buy rating but cut its price target to $230 from $270. This could attract value investors and support the stock.
This provides a potential positive catalyst and shows analyst views on valuation after the decline.

17 Jul – 24 Jul 2026

▲2▼2

Danaher's Q2 Beat Marred by Weak Guidance and Biotech Shipment Shift

Weak Q3 revenue guidance triggers sell-off Danaher guided Q3 core revenue growth to just 2-3%, far below expectations, despite beating Q2 estimates. This signals slower demand ahead, pushing the stock down sharply as investors worry about future growth.
This is the main new event that caused the stock to drop over 10% this period.
Biotech consumables sales miss due to shipment timing High-margin biotech consumables missed expectations because a few large chromatography resin shipments moved out of the year. This reduces near-term revenue and profit, and the market fears it could signal broader weakness.
This explains the specific reason behind the guidance cut and the stock's decline.
Q2 earnings beat and raised full-year EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45-$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.
This is a key positive from the quarter that contrasts with the negative reaction.
Analysts see sell-off as overreaction and buying opportunity The 12% weekly drop is viewed by some analysts as an overreaction to a timing issue, not a fundamental problem. If shipments shift to later quarters, revenue will still be recognized, making the decline a potential buying opportunity for long-term investors.
This provides a counterweight to the negative news and suggests the stock may rebound.

24 Jun – 9 Jul 2026

▲3▼1

Danaher's Masimo Bet Faces Doubts as Core Biotech Shows Strength

Masimo acquisition drags on stock Danaher's $9.9 billion purchase of Masimo has pushed shares down 22% this year. Investors worry about added debt, integration challenges, and a patent fight with Apple. This weighs on the stock because it increases risk and uncertainty.
Explains the main reason DHR is down this year and the key overhang on the stock.
Masimo unit gets FDA clearance for AI opioid detection Masimo received FDA clearance for an AI feature that detects opioid-induced breathing problems. This is a first-of-its-kind product that could boost sales and shows the acquisition is already producing innovative products, lifting investor sentiment.
Shows a concrete positive from the Masimo deal that could drive future revenue and improve sentiment.
Biotech segment core revenues grow 7% Danaher's Biotechnology segment saw core revenues rise 7% in Q1 2026, with bioprocessing equipment orders up over 30%. This indicates strong demand for the company's core products, which supports revenue growth and profitability, pushing the stock up.
Highlights the strong performance of Danaher's core business, a key driver of earnings and stock price.
Beckman Coulter wins CE Mark for Alzheimer's blood test Danaher's Beckman Coulter received CE Mark for its p-Tau217 blood assay, allowing sales in Europe. This regulatory win opens a new market for a potentially high-demand Alzheimer's test, adding a future revenue stream and boosting the stock.
Represents a new product approval that expands Danaher's diagnostics offerings and could drive growth.